Get the Stockscreener App
96.88
0.29%
0.28
After Hours:
96.84
-0.04
-0.04%
Boston Scientific Corp stock is traded at $96.88, with a volume of 13.39M.
It is up +0.29% in the last 24 hours and down -3.02% over the past month.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
See More
Previous Close:
$96.60
Open:
$96.45
24h Volume:
13.39M
Relative Volume:
1.47
Market Cap:
$143.62B
Revenue:
$19.35B
Net Income/Loss:
$2.78B
P/E Ratio:
51.82
EPS:
1.8696
Net Cash Flow:
$3.82B
1W Performance:
-5.66%
1M Performance:
-3.02%
6M Performance:
-7.42%
1Y Performance:
+5.88%
1-Day Range:
$96.07
$98.34
1-Week Range:
$95.98
$102.70
52-Week Range:
$85.98
$109.50
Boston Scientific Corp Stock (BSX) Company Profile
Name
Boston Scientific Corp
Sector
Industry
Phone
508-683-4000
Address
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Compare BSX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
96.88 | 143.20B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
ABT
Abbott Laboratories
|
128.11 | 215.57B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
SYK
Stryker Corp
|
368.27 | 137.86B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
101.20 | 127.43B | 34.76B | 4.79B | 5.21B | 3.7049 |
|
EW
Edwards Lifesciences Corp
|
85.13 | 48.80B | 5.88B | 1.34B | 799.60M | 2.3489 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-03-25 | Downgrade | Erste Group | Buy → Hold |
| Sep-08-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-16-25 | Initiated | Leerink Partners | Outperform |
| Apr-16-25 | Upgrade | Needham | Hold → Buy |
| Jan-10-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Oct-18-24 | Downgrade | Needham | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Feb-01-24 | Upgrade | Mizuho | Neutral → Buy |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Jun-30-23 | Initiated | CL King | Buy |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Buy |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-20-22 | Resumed | Citigroup | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-06-22 | Initiated | Wolfe Research | Outperform |
| May-27-22 | Upgrade | Needham | Hold → Buy |
| Apr-13-22 | Resumed | Truist | Buy |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| May-26-21 | Downgrade | Needham | Buy → Hold |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Sep-17-20 | Initiated | Truist | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Peer Perform |
| Apr-22-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-01-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Buy |
| Dec-30-19 | Reiterated | Cowen | Outperform |
| Dec-19-19 | Downgrade | Needham | Strong Buy → Buy |
| Sep-05-19 | Resumed | JP Morgan | Overweight |
| Sep-03-19 | Resumed | Barclays | Overweight |
| May-13-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-28-18 | Initiated | UBS | Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Oct-02-18 | Reiterated | Morgan Stanley | Overweight |
| Sep-07-18 | Reiterated | Needham | Strong Buy |
| Sep-04-18 | Upgrade | Jefferies | Hold → Buy |
| Jul-06-18 | Reiterated | Needham | Strong Buy |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Apr-26-18 | Reiterated | Needham | Strong Buy |
View All
Boston Scientific Corp Stock (BSX) Latest News
Analysts project durable growth with many near-term catalysts for Boston Scientific - MassDevice
BTIG Reiterates Boston Scientific (BSX) Buy Recommendation - Nasdaq
Internal Neuromodulation Devices Market Poised to Exceed USD 44.57 Billion by 2033 | Astute Analytica - GlobeNewswire Inc.
Can Boston Scientific Corporation stock sustain institutional flowsMarket Activity Report & AI Driven Stock Reports - newser.com
Will Boston Scientific Corporation stock benefit from automation - newser.com
Is Boston Scientific Corporation stock undervalued after correctionJuly 2025 Big Picture & Safe Entry Momentum Tips - newser.com
Boston Scientific (BSX) Announces 2026 Compensation Plans to Dri - GuruFocus
Boston Scientific, Epic collaborate on cardiac diagnostic EHR services - MassDevice
Boston Scientific Approves 2026 Bonus Plan - TipRanks
Boston Scientific Corp. Stock Outperforms Competitors Despite Losses On The Day - 富途牛牛
[8-K] BOSTON SCIENTIFIC CORP Reports Material Event | BSX SEC FilingForm 8-K - Stock Titan
Boston Scientific (BSX) Stock Today: Price Slips as Neuromodulation Bull Case, Epic EHR Deal and Big Fund Moves Shape the Outlook – November 19, 2025 - ts2.tech
Siemens partners with Boston Sci, eyes standalone growth - BioWorld MedTech
Using AI based signals to follow Boston Scientific Corporation2025 Performance Recap & Advanced Technical Analysis Signals - newser.com
Can Boston Scientific Corporation stock deliver consistent EPS growth2025 Sector Review & Daily Chart Pattern Signal Reports - newser.com
Does Boston Scientific Corporation stock trade at a discount to peersWeekly Volume Report & Entry and Exit Point Strategies - newser.com
Boston Scientific at Wolfe Conference: Innovation and Market Growth - Investing.com
Wall Street Analysts Believe Boston Scientific (BSX) Could Rally 25.34%: Here's is How to Trade - Finviz
Zacks Industry Outlook Highlights Boston Scientific, Insulet, BioLife Solutions and Allurion - Nasdaq
Can Boston Scientific Corporation recover in the next quarterNew Guidance & Free Accurate Trade Setup Notifications - newser.com
Why Boston Scientific Corporation stock is favored by hedge fundsWeekly Trade Report & Free High Accuracy Swing Entry Alerts - newser.com
2 Reasons to Watch BSX and 1 to Stay Cautious - Finviz
What earnings revisions data tells us about Boston Scientific Corporation2025 Retail Activity & Risk Controlled Daily Trade Plans - newser.com
Is Boston Scientific's Valuation Justified After 18% Gain and New Product Launches? - Yahoo Finance
What Boston Scientific (BSX)'s Surging Sales and Siemens Partnership Mean for Shareholders - Yahoo! Finance Canada
[Form 4] BOSTON SCIENTIFIC CORP Insider Trading Activity - Stock Titan
Boston Scientific Corp. stock underperforms Friday when compared to competitors - MarketWatch
Boston Scientific gains US distribution duties for Siemens Healthineers’ ICE catheter - Yahoo Finance
Boston Scientific Up 7% in a Month: How Should You Play the Stock? - Finviz
Can Boston Scientific Corporation stock test all time highsQuarterly Portfolio Report & Weekly High Conviction Ideas - newser.com
UBS Boosts Boston Scientific (BSX) Price Target After Strong Q3 Earnings - Insider Monkey
Boston Scientific, Siemens Healthineers ink 4D ICE catheter development deal - MassDevice
Boston Scientific enrolls first patient in AFib mapping study using OptiMap, Farapulse - MassDevice
Boston Scientific (BSX) Crossed Above the 200-Day Moving Average: What That Means for Investors - Yahoo Finance
Investors more bullish on Boston Scientific (NYSE:BSX) this week as stock grows 3.7%, despite earnings trending downwards over past five years - Yahoo Finance
CLOSURE-AF study not the end of the line for LAAC devices - BioWorld MedTech
Brokers Suggest Investing in Boston Scientific (BSX): Read This Before Placing a Bet - Yahoo Finance
If You Invested $1000 in Boston Scientific a Decade Ago, This is How Much It'd Be Worth Now - Yahoo Finance
Is Boston Scientific (BSX) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance
Boston Scientific Corp Stock (BSX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):